Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 2
2011 1
2012 3
2013 2
2014 7
2015 3
2016 3
2017 8
2018 6
2019 5
2020 6
2021 2
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: dronca rs. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. Mosalem O, et al. Among authors: dronca rs. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00799-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341460
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. Smith KER, et al. Among authors: dronca rs. Front Immunol. 2023 Oct 31;14:1279387. doi: 10.3389/fimmu.2023.1279387. eCollection 2023. Front Immunol. 2023. PMID: 38022659 Free PMC article. Clinical Trial.
Patient- and Provider-Level Factors Associated With Telehealth Utilization Across a Multisite, Multiregional Cancer Practice From 2019 to 2021.
Pritchett JC, Borah BJ, Dholakia R, Moriarty JP, Ahn HH, Huang M, Khera N, Wilshusen L, Dronca RS, Ticku J, Leppin AL, Tilburt JC, Paludo J, Haddad TC. Pritchett JC, et al. Among authors: dronca rs. JCO Oncol Pract. 2023 Sep;19(9):750-758. doi: 10.1200/OP.23.00118. Epub 2023 Jun 19. JCO Oncol Pract. 2023. PMID: 37335959 Free PMC article.
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.
Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H. Wen T, et al. Among authors: dronca rs. Cancer Immunol Res. 2022 Feb;10(2):162-181. doi: 10.1158/2326-6066.CIR-21-0539. Epub 2021 Dec 15. Cancer Immunol Res. 2022. PMID: 34911739 Free PMC article.
Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications.
ReFaey K, Tripathi S, Grewal SS, Bhargav AG, Quinones DJ, Chaichana KL, Antwi SO, Cooper LT, Meyer FB, Dronca RS, Diasio RB, Quinones-Hinojosa A. ReFaey K, et al. Among authors: dronca rs. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun 8;5(3):645-653. doi: 10.1016/j.mayocpiqo.2021.05.005. eCollection 2021 Jun. Mayo Clin Proc Innov Qual Outcomes. 2021. PMID: 34195556 Free PMC article.
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. Orme JJ, et al. Among authors: dronca rs. Oncoimmunology. 2020 Apr 14;9(1):1744980. doi: 10.1080/2162402X.2020.1744980. eCollection 2020. Oncoimmunology. 2020. PMID: 32363112 Free PMC article.
49 results